Magnetization controlled by crystallization in soft magnetic Fe-Si-B-P-Cu alloys.

Soft magnetic materials have low coercive fields and high permeability. Recently, nanocrystalline alloys obtained using annealing amorphous alloys have attracted much interest since nanocrystalline alloys with small grain sizes of tens of nanometers exhibit low coercive fields comparable to that of amorphous alloys. Since nanocrystalline soft magnetic materials attain remarkable soft magnetic properties by controlling the grain size, the crystal grains' microstructure has a substantial influence on the soft magnetic properties.

Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.

Objective: This is the first clinical trial for Japanese to evaluate the dose-response and determine the clinically effective dose of darbepoetin alpha by weekly subcutaneously administration in anemic patients with lung cancer or ovarian cancer receiving chemotherapy.

Methods: Eligible patients were required to have anemia (hemoglobin level of View Article and Find Full Text PDF

Axillary mass suspected to be occult breast carcinoma: a case study of skipped axillary lymph node metastasis from endometrial carcinoma in which core-needle biopsy was useful for diagnosis.

A 55-year-old Japanese woman presented with metrorrhagia and was diagnosed with endometrial carcinoma. Chest computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) showed a left axillary mass. Regarding the diagnosis of the axillary mass, lymph node metastasis from the uterus was first suspected.

A patient with stage 1a endometrial carcinoma in whom a solitary recurrent lesion was detected in the external iliac lymph node after MPA therapy.

Background: In the treatment of endometrial carcinoma, young patients desire the preservation of the uterus, and therefore hormonal therapy has been administered.

Case Report: The patient was a 39-year-old nullipara diagnosed with stage 1a endometrial carcinoma. The patient desired the preservation of the uterus, and oral administration of MPA was prescribed for 18 weeks, which after the cancer tissue disappeared.

A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin.

Glassy cell carcinoma of the uterine cervix is a rare tumor, and has a poor prognosis because of its aggressive clinical behavior and resistance to radiotherapy and chemotherapy. We report a case of bulky glassy cell carcinoma of the uterine cervix that effectively responded to paclitaxel and carboplatin in a neoadjuvant setting. The patient was a 30-year-old woman who became aware of vaginal bleeding and was referred to our hospital because of a cancerous tumor of the uterine cervix.

[Clinical development of OCT].

OCT was first synthesized in the late 1980s, and clinical development was started in July 1991 with entry into Phase I. By the time the application for manufacturing approval was submitted, in February 1998, 15 clinical studies had been carried out, including 2 double-blind comparative studies and 5 long-term administration studies. The efficacy and safety of OCT were evaluated on the basis of clinical data obtained from totally 977 participants.

[High-dose-rate interstitial brachytherapy using inverse planning for locally advanced cervical cancer].

A 56-year-old woman with bulky cervical cancer was treated with high-dose-rate interstitial brachytherapy combined with external beam irradiation and chemotherapy. Inverse planning (IP) was used in the treatment planning for brachytherapy. Source dwell positions were selected automatically, once the required information had been input, for example, to prohibit dwelling inside the organs at risk (OARs) and to permit dwelling inside the planning target volume with a 2-mm inner margin.

Tosulfoxacin Treatment of Chlamydia Trachomatis Infection of the Uterine Cervix.

In vivo efficacy of tosufloxacin (TFLX) for treatment of Chlamydia trachomatis cervical infection in women was evaluated by enzyme immunoassay. The short term (within 31 days of treatment) response rates with a dosage of 150mg orally 3 times daily were 100% (54/54) with 14 days of treatment and 97% (38/39) with 7 days of treatment. Subjective symptoms such as lower abdominal pain, vaginal discharge, or atypical bleeding were observed in 76 (82%) of the 93 patients.